newsfilter
← Latest News
GlobeNewswire·

Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026

  • Eisai Co., Ltd. and Biogen Inc. presented findings from a Clarity AD cerebrospinal fluid substudy at the 19th CTAD conference regarding lecanemab treatment & α-synuclein co-pathology in early Alzheimer's disease.
  • Analysis of 623 CSF samples revealed that α-synuclein pathology prevalence was significantly higher in amyloid-beta positive (Aβ+) participants (20.4%) compared to Aβ-negative participants (10.0%).
  • Participants with α-synuclein co-pathology exhibited higher baseline amyloid burden (86 Centiloids vs. 67 Centiloids) & experienced faster clinical decline over 18 months compared to those without the co-pathology.
  • Lecanemab demonstrated a slowing of clinical decline at Month 18 in both the overall α-synuclein-tested group & the α-synuclein-positive subgroup compared to placebo.
  • Reduction in clinical decline for the α-synuclein-positive group was measured at 41% by CDR-SB, 43% by ADAS-Cog14, & 43% by ADCS MCI-ADL.
  • These results indicate that lecanemab provides clinical benefit to individuals with early Alzheimer's disease even when α-synuclein co-pathology is present.
  • Eisai leads the global development & regulatory submissions for lecanemab, with both companies co-commercializing the product under Eisai's final decision-making authority.
Company
Biogen Inc.
Keywords
Nasdaq:BIIB, Biogen Inc.